309 related articles for article (PubMed ID: 8840095)
1. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
Heinemann L; Heise T; Wahl LC; Trautmann ME; Ampudia J; Starke AA; Berger M
Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
[TBL] [Abstract][Full Text] [Related]
2. Counterregulatory hormone responses and symptoms during hypoglycaemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin Lispro) in healthy male volunteers.
Jacobs MA; Salobir B; Popp-Snijders C; Ader H; Heine RJ
Diabet Med; 1997 Mar; 14(3):248-57. PubMed ID: 9088775
[TBL] [Abstract][Full Text] [Related]
3. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.
Annuzzi G; Del Prato S; Arcari R; Bellomo Damato A; Benzi L; Bruttomesso D; Calderini MC; Coscelli C; Fedele D; Galluzzo A; Giordano M; Giorgino R; Lapolla A; Orsini P; Pagano G; Santoro D; Riccardi G
Nutr Metab Cardiovasc Dis; 2001 Jun; 11(3):168-75. PubMed ID: 11590992
[TBL] [Abstract][Full Text] [Related]
4. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia.
Howey DC; Bowsher RR; Brunelle RL; Rowe HM; Santa PF; Downing-Shelton J; Woodworth JR
Clin Pharmacol Ther; 1995 Oct; 58(4):459-69. PubMed ID: 7586939
[TBL] [Abstract][Full Text] [Related]
5. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
[TBL] [Abstract][Full Text] [Related]
6. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
[TBL] [Abstract][Full Text] [Related]
7. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
[TBL] [Abstract][Full Text] [Related]
8. Treatment of type 1 diabetes with insulin lispro during Ramadan.
Kadiri A; Al-Nakhi A; El-Ghazali S; Jabbar A; Al Arouj M; Akram J; Wyatt J; Assem A; Ristic S
Diabetes Metab; 2001 Sep; 27(4 Pt 1):482-6. PubMed ID: 11547222
[TBL] [Abstract][Full Text] [Related]
9. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
[TBL] [Abstract][Full Text] [Related]
10. [Insulin Lispro (Lys B28, Pro B29) treatment in adolescents and young people with type 1 diabetes].
Tuset Castellano MJ; Martínez Badás I; Alonso Blanco M; Barrio Castellanos R
An Esp Pediatr; 2000 Apr; 52(4):334-8. PubMed ID: 11003924
[TBL] [Abstract][Full Text] [Related]
11. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.
Perriello G; Pampanelli S; Porcellati F; Avogaro A; Bosi E; Petrella G; Squatrito S; Furneri S; Marra G; Vitali L; Previti M; Cucinotta D
Diabet Med; 2005 May; 22(5):606-11. PubMed ID: 15842516
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus.
Jehle PM; Fussgänger RD; Seibold A; Lüttke B; Böhm BO
Int J Clin Pharmacol Ther; 1996 Nov; 34(11):498-503. PubMed ID: 8937933
[TBL] [Abstract][Full Text] [Related]
13. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
Reichel A; Rietzsch H; Köhler HJ; Pfützner A; Gudat U; Schulze J
Exp Clin Endocrinol Diabetes; 1998; 106(3):168-72. PubMed ID: 9710355
[TBL] [Abstract][Full Text] [Related]
14. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J
Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
[TBL] [Abstract][Full Text] [Related]
15. [From the concept of fast acting analogs to the properties of the insulin Lispro].
Selam JL
Diabetes Metab; 1997 Sep; 23 Suppl 3():45-9. PubMed ID: 9410552
[TBL] [Abstract][Full Text] [Related]
16. Insulin lispro improves postprandial glucose control in patients with diabetes mellitus.
Skrha J; Smahelová A; Andĕl M; Vrtovec M; Subić J; Kreze A; Vozar J; Korecová M; de Verga V; Wyatt J; Metcalfe S; Ristić S
Sb Lek; 2002; 103(1):15-21. PubMed ID: 12448933
[TBL] [Abstract][Full Text] [Related]
17. Effect of the insulin analogue [LYS(B28),PRO(B29)] on blood glucose control.
Trautmann ME
Horm Metab Res; 1994 Dec; 26(12):588-90. PubMed ID: 7705764
[TBL] [Abstract][Full Text] [Related]
18. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
[TBL] [Abstract][Full Text] [Related]
19. [Rapid-acting insulin analogues].
Matsuda A; Kuzuya T
Nihon Rinsho; 1999 Mar; 57(3):709-18. PubMed ID: 10199158
[TBL] [Abstract][Full Text] [Related]
20. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
Ashwell SG; Gebbie J; Home PD
Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
